Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

Su KP, Huang SY, Chiu CC, Shen WW.

Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71. Erratum in: Eur Neuropsychopharmacol. 2004 Mar;14(2):173.

PMID:
12888186
2.

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.

da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC.

J Affect Disord. 2008 Dec;111(2-3):351-9. doi: 10.1016/j.jad.2008.03.008. Epub 2008 May 15.

PMID:
18485485
3.

Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial.

Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM.

J Clin Psychiatry. 2008 Apr;69(4):644-51.

PMID:
18370571
4.

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.

PMID:
20124114
5.

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.

Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB.

Arch Gen Psychiatry. 1999 May;56(5):407-12.

PMID:
10232294
7.

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.

Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S.

Am J Clin Nutr. 2009 Feb;89(2):641-51. doi: 10.3945/ajcn.2008.26749. Epub 2008 Dec 30.

8.

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.

Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K.

Arch Gen Psychiatry. 2004 Dec;61(12):1235-44.

PMID:
15583115
9.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
10.

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.

Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1538-44. doi: 10.1016/j.pnpbp.2008.05.015. Epub 2008 May 25.

PMID:
18573585
11.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
12.

n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers.

Buydens-Branchey L, Branchey M.

J Clin Psychopharmacol. 2006 Dec;26(6):661-5.

PMID:
17110827
13.

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

Kennedy SH, Emsley R.

Eur Neuropsychopharmacol. 2006 Feb;16(2):93-100. Epub 2005 Oct 24.

PMID:
16249073
14.

The efficacy of omega-3 supplementation for major depression: a randomized controlled trial.

Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR.

J Clin Psychiatry. 2011 Aug;72(8):1054-62. doi: 10.4088/JCP.10m05966blu. Epub 2010 Jun 15.

PMID:
20584525
15.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
16.

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.

Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B.

Arch Gen Psychiatry. 2007 Jun;64(6):679-88.

PMID:
17548749
17.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
18.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
19.

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.

Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.

Arthritis Rheum. 2004 Sep;50(9):2974-84.

20.

The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.

Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101.

PMID:
17909125
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk